Kornimate/medical-research-clean huggingface dataset:
development and exploration of the feasibility of using locally synthesized small molecule inhibitors to treat human acute leukemia cells

Conditions: Acute Myeloid Leukemia

Summary: acute leukemias are commonly seen in elderly and have no effective therapy. in recent years, small molecule inhibitors have shown a tremendous promise in cancer treatment such as chronic myeloid leukemia and lung cancer. thus, in this proposal, we intend to use our novel patented "indole" compound to conjugated with hydroxamic acid in histone deacetylases inhibitor, suberoylanilide hydroxamic acid and further modify its structure to generate novel small-molecule anticancer compounds. by screening acute leukemic cell lines, we will look for compounds that have shown potential for future drug development. in our preliminary studies, we have identified a novel compound, mpt0e001, to have marked growth inhibitory activity, induce apoptosis and downregulate c-myc protein level. we intend to use mpt0e001 as a basis to develop novel compounds and test them in multiple leukemic cell lines and primary leukemia samples (specific aim 1) and identify the mechanisms for downregulation of c-myc and other pathways such as nf-kappab and akt (specific aim 2). once we have identified the lead compounds, we will use murine model to assess the acute toxicity profiles in different dose ranges and examine the effects of blood counts and vital organs. after toxicity study, we will test the lead compounds using in vivo xenogenic murine model using both cell lines and primary leukemia. using this approach, we hope to develop novel compounds that are able to be used in future leukemic therapy.


Eligibility criteria:
inclusion criteria: * acute myeloid leukemia exclusion criteria: * hematologic malignancies other than aml

Keywords: aml
a pharmacokinetic study of ro4917838 in healthy chinese volunteers

Conditions: Healthy Volunteer

Summary: this single-center, open-label, single dose, randomized, two-way cross-over study will evaluate the pharmacokinetics, safety and tolerability of ro4917838 in healthy chinese volunteers. subjects will be randomized to receive a single oral dose of either 10 mg or 20 mg ro4917838 and, after a washout period of at least 21 but no more than 35 days, will be re-dosed with the alternative treatment. anticipated time on study is up to 70 days.


Eligibility criteria:
inclusion criteria: * healthy chinese male and female volunteers, 18 to 45 years of age inclusive at time of screening * healthy status is defined by absence of evidence of any active or chronic disease or disorder following a detailed medical and surgical history and a complete physical examination * body mass index (bmi) 19 to 28 kg/m2 inclusive exclusion criteria: * pregnant or currently lactating females * history of any clinically relevant disorder * any history of depressive episodes or treatment with antidepressants * history of drug abuse within the past 2 years or positive results for drugs of abuse at screening or day -1 * alcohol dependence or history of this within the past 2 years or positive results for alcohol breath test at screening or day -1 * positive for hiv, hepatitis b or hepatitis c infection * regular smoker with consumption of more than 10 cigarettes a day or equivalent amount of tobacco * participation in a clinical study with an investigational drug or device within the last 3 months prior to dosing * medical history of significant drug allergies
efficacy and safety of temodal vs semustine in subjects with recurrent glioblastoma or anaplastic astrocytoma (study p03644)

Conditions: Glioblastoma; Astrocytoma

Summary: the primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.


Eligibility criteria:
inclusion criteria: * prior histologic confirmation of glioblastoma, anaplastic astrocytoma. * evidence of tumor progression or recurrence. * age \>=18 years. * karnofsky performance status \>=60%. * absolute neutrophil count \>=1,500/mm\^3, platelet count \>=100,000/mm\^3, hemoglobin \>=8g/dl. * serum bun and creatinine \<1.5 times upper normal limit of testing laboratory (uln). * total bilirubin and direct bilirubin \<1.5 times uln. * sgot, sgpt \<3 times uln; alkaline phosphatase \<2 times uln. * life expectancy greater than 3 months. * informed consent obtained. * if palliative radiation is needed, agree to give it prior to initiating chemotherapy with study drug. if palliative radiation is required during treatment with study drug, the patient should be permanently discontinued from further treatment with study drug. * women of childbearing potential must use a medically accepted, effective method of contraception. * women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug. exclusion criteria: * chemotherapy (excluding nitrosourea, mitomycin c or vincristine), biologic therapy or immunotherapy within 4 weeks, inclusive, prior to study drug administration. * nitrosourea or mitomycin c administration within 6 weeks, inclusive, prior to study drug administration. * vincristine within 2 weeks prior to study drug administration. * completion of radiation therapy, interstitial brachytherapy or radiosurgery within 4 weeks prior to study drug administration. * surgery within 3 weeks, inclusive, prior to study drug administration. * acute infection requiring intravenous antibiotics. * frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction). * previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin. * known hiv positive or aids-related illness. * pregnant or nursing women. * men who are not advised to use an effective method of contraception.
evaluation of xylitol wipes as an oral hygiene protocol for haemophilic children

Conditions: Haemophilia

Summary: the purpose of this study is to evaluate xylitol wipes as an oral hygiene protocol for haemophilic children


Eligibility criteria:
inclusion criteria: * hemophilic children a or b with no other systemic diseases. * aged (6-12 years). * co-operative. exclusion criteria: * children on long-term antibiotics
belotaxel(docetaxel) and belloxa(oxaliplatin) in advanced nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: lung cancer is the leading cause of cancer death in korea as well as in other countries. about 80% of lung cancer is non-small cell lung cancer(nsclc). the majority of patients with nsclc require cytotoxic chemotherapy in the course of their illness. combination chemotherapy using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with platinums(cisplatin or carboplatin) reached a plateau in their efficacy. oxaliplatin, another platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects such as nausea and nephrotoxicity. in this phase ii trial, we will observe efficacy and safety of docetaxel and oxaliplatin for patients with nsclc.


Eligibility criteria:
inclusion criteria: * stage iiib/iv or relapsed nsclc * age \>= 18 years * at least one measurable lesion by recist (version 1.1) * ecog ps 0, 1, 2 * hematologic profile * hgb \> 8 g/dl, anc \>= 2,000/m3, platelet \>= 100,000/m3 * hepatic profile * total bilirubin \<= 1.5 x upper normal value * transaminases \<= 3 x upper normal value \<= 5 x upper normal value in case of liver metastasis * creatinine \<= 1.5mg/dl * patients should be recovered from toxicities of previous treatment. * written informed consent by patient or surrogates exclusion criteria: * patients who had been previously treated with chemotherapy for nsclc * active infection requiring antibiotics treatment * prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix * peripheral neuropathy \>= grade 2 by nci ctcae 4.0 * uncontrolled hypertension, acute myocardial infarction within 6 months unstable angina, congestive heart failure \>= nyha grade 2 uncontrolled significant arrhythmia * patients who entered other clinical trials within 4 weeks * pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure

Keywords: nsclc
effect of an educational nail biopsy video on pre-operative anxiety, health literacy, and patient satisfaction

Conditions: Anxiety; Literacy; Satisfaction, Patient

Summary: the investigators are interested in studying the effect of an animated video depicting a nail biopsy procedure on the anxiety, health literacy, and satisfaction of participants recommended to undergo a nail biopsy procedure. the investigators hypothesize that the animated video will reduce preoperative anxiety, increase health literacy, and increase patient satisfaction in relation to nail biopsy procedures.


Eligibility criteria:
inclusion criteria: * all patients recommended to receive a nail biopsy procedure in our specialty nail clinic. exclusion criteria: * age less than 18
real-world study of treatment outcomes in chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (cidp)

Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic

Summary: this study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (cidp) diagnosis in the united states with residual impairment, disability, or neurological deficits after at least three months of treatment with standard of care therapy. the study is expected to last two years. enrollment is expected to continue for one year. depending on when the participant is enrolled, a participant can be followed for between one and two years, through the end of study, approximately two years after the study starts.


Eligibility criteria:
inclusion criteria: participants are eligible to be included in the study only if all of the following criteria apply: * neurologist-confirmed diagnosis of cidp found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed * active use of at least one of the following cidp treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment * immunoglobulin * corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day * plasma exchange * efgartigimod alfa * azathioprine * mycophenolate mofetil * cyclosporine * rituximab * methotrexate * signed informed consent * residual impairment, disability, or neurological deficits at enrollment, as defined by a raw i-rods score of 44 or below exclusion criteria: participants are excluded from the study if any of the following criteria apply: * evidence of participation in any interventional clinical trial with an investigational drug at the time of enrollment * hyperreflexia (increased reflexes) recorded in the medical record during a neurological exam the year before enrollment and after cidp diagnosis * aged under 18 at the time of enrollment the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
evaluation of pain quality in young swimmers suffering from myofascial pain syndrome using lidocaine phonophoresis

Conditions: Neck Pain

Summary: to evaluate pain quality by pain quality assessment scale (pqas) using lidocaine phonophoresis on myofascial pain syndrome (mps) in athletic children.

forty five males athletic swimmer children (10 to 14 years old) with mps in the upper trapezius muscle were evaluated before and after treatment. they were randomly divided into three groups, n=15 children each. a (control), b and c (study groups). the three groups received spatial designed physical therapy program. the two study groups received pulsed ultrasound and lidocaine phonophoresis repectively. the duration of treatment was 40 minutes, three times / weeks for three successive months.

Eligibility criteria:
inclusion criteria: * age range from 10 to 14 years. * all children have regional neck pain complaint. * tenderness in cervical trigger points in the midpoint of the upper border of trapezius muscle, from grade ii to grade iv according to tenderness grading scheme (hubbard and berkoff, 1993) (appendix i ) * the diagnosis of an active mtrp in the upper trapezius according to (ardiçet al . , 2002 and bruno, 2005): * patients suffered from active mtrps in the upper trapezius. * tender spots in one or more palpable taut bands. * a typical pattern of referred pain distributed in the ipsilateral, posterolateral cervical paraspinal area, mastoid process or temporal area * palpable or visible local twitch response on snapping palpation at the most sensitive spot in the taut band. * restricted range of motion in lateral bending of the cervical spine to the opposite side. * palpation of a trigger point elicits a stereotypic zone of referred pain specific to that muscle. * identification of a palpable taut band, as well as a palpable, and exquisitely tender spot along the length of that taut band. * all children allowed to practice their regular sport activities. exclusion criteria: * neurological disorders. * dermatological disorders. * acute trauma prior to the study. * fibromyalgia, systemic disease and drug allergy history were excluded from the study. * having myofascial trigger points injection. * chronic pain in both sides of the body. * history of findings of cervical injury whether orthopedic or soft tissue injury

Keywords: myofascial phonophoresis pain
tst001 in patients with cldn18.2 positive previously treated advanced biliary tract cancer

Conditions: Biliary Tract Neoplasms

Summary: tst001 is a recombinant humanized anti-claudin 18.2 (cldn18.2) igg1 monoclonal antibody. this is an open-label, single-arm phase ii study to evaluate the efficacy and safety of tst001 for patients with cldn18.2 positive previously treated unresectable advanced or metastatic biliary tract cancer.

tst001 is a recombinant humanized anti-claudin 18.2 (cldn18.2) igg1 monoclonal antibody. claudin18.2 (cldn18.2) protein is one of the family of tetraspanning proteins expressed at epithelial tight junctions and primarily expressed only in normal gastric tissues . cldn18.2 protein is a pancancer target expressed in primary lesions and metastases of variouscancer types, including gastric cancer, biliary tract cancer and others. current available information indicates that cldn18.2 is a promising therapeutic target for the treatment of solid tumors. this is an open-label, single-arm phase ii study to evaluate the efficacy and safety of tst001 for patients with cldn18.2 positive previously treated unresectable advanced or metastatic biliary tract cancer. eligible patients will be treated with tst001 until disease progression or other discontinuation criteria met. if there is ≥ one objective response among the first 15 enrolled patients, then the trial continues to enroll a total of 40 patients; if not, then the trial discontinues.

Eligibility criteria:
inclusion criteria: * histologically confirmed, unresectable advanced or metastatic biliary tract cancer. * patients failed at least one prior line of systemic medications; if patients had disease progression during or within 6 months after the completion of adjuvant therapy or neoadjuvant therapy, the adjuvant therapy or neoadjuvant therapy could be regarded as one line of therapy. * cldn18.2 expression positive confirmed through tumor tissue. * patients with at least one measurable disease according to recistv1.1. * ecog ps of 0 or 1. * patients have predicted life expectancy ≥ 12 weeks. * paitients with adequate cardica, liver, renal function, etc. exclusion criteria: * • history of another concurrent primary malignancy. * untreated or symptomatic cns metastases. * prior treatment targeting cldn18.2. * major surgical procedure, prior locoregional therapy such as radioembolization within 28 days prior to the first dose of study drug. * prior serious hypersensitivity to monoclonal antibody or any component of the investigational drug. * patients had any of the following within 6 months prior to first dose of study treatment: cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris, heart failure nyha iii or iv degree, or uncontolled uarrhythmia requiring intervention. * patients who are pregnant or lactating.
dp-r212 pharmacokinetic study

Conditions: Hypertension; Hyperlipidemias

Summary: an open-label, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction of amlodipine and rosuvastatin in healthy adult male subjects.


Eligibility criteria:
inclusion criteria: * bmi 18-29 * signed the informed consent form prior to the study participation exclusion criteria: * clinically significant disease * previously donate whole blood within 60 days or component blood within 14 days * clinically significant allergic disease * taken ip in other trial within 90 days * an impossible one who participates in clinical trial by investigator's decision including laboratory test result
a first-in-human study of ro5503781 in participants with advanced malignancies except leukemia

Conditions: Neoplasms

Summary: this multicenter, open label, dose-escalating study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ro5503781, administered once daily (qd) or once weekly (qw) in participants with advanced malignancies except leukemia. participants will receive multiple escalating oral doses in two different dosing schedules (sch) until disease progression or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced malignancies, except all forms of leukemia, for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the participants * measurable disease (according to recist or cheson criteria) or evaluable disease prior to administration of study drug * minimum weight of 35 kg and life expectancy of greater than or equal to (\>=) 12 weeks * eastern cooperative oncology group (ecog) performance status of 0 to 1 * acute toxicities from any prior anti-tumor therapy, surgery, or radiotherapy must have resolved to nct-ctcae grade less than or equal to (\<=) 1 * adequate renal, hepatic and bone marrow function * participants with stable central nervous system (cns) metastasis and with chronic, stable and rate controlled atrial fibrillation * participants in consideration for the biomarker cohorts or apoptosis imaging cohort must consent and be able to undergo paired biopsies for tumor biomarker analyses * able to participate and willing to give written informed consent and to comply with the study restrictions exclusion criteria: * history of any form of leukemia except for stage 0 and 1 chronic lymphocytic leukemia (cll) not requiring treatment in addition to the underlying solid tumor * use of hormonal therapy within 2 weeks and use of other investigational agents or having received investigational drugs \<= 4 weeks prior to study treatment start * history of seizure disorders or unstable cns metastases * severe and/or uncontrolled cardiovascular disease or disorder * active (acute or chronic) or uncontrolled infection * pregnant or breastfeeding women * hiv-positive participants who are currently receiving anti-retroviral treatment * known coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia * participants receiving oral or parenteral anticoagulants/antiplatelet agents; anticoagulant flushes for maintenance of indwelling catheters are allowed * participants with known bone marrow disorder which may interfere with bone marrow recovery * participants with hypersensitivity reaction to 18fluorothymidine (flt or 18f) compounds
flu vaccine responses in the setting of melanoma treatment

Conditions: Viral Vaccines

Summary: influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. we are conducting a prospective unblinded study of influenza vaccine recipients.

influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. in particular, immune responses following influenza vaccination have not been studied in the setting of advanced melanoma and in the context of various anti-tumor treatments. in this study, we will look at the immune response of subjects receiving vaccination.

Eligibility criteria:
inclusion criteria: * adults capable of providing consent * have a diagnosis of locally advanced or metastatic melanoma exclusion criteria: * are allergic to influenza vaccination * have received influenza vaccination within the past 6 months * require prednisone, methotrexate, or other immunosuppressing medications * have hiv infection * have a history of solid organ or bone marrow transplant * require combination immunotherapy * are on other studies requiring blood draws that might exceed 450 ml total during the period of the influenza vaccine study

Keywords: influenza vaccine
epidural anesthesia and postoperative analgesia with ropivacaine and fentanyl

Conditions: Coronary Artery Disease

Summary: the aim of the present study was to assess the efficacy of thoracic epidural anesthesia followed by postoperative epidural infusion and patient-controlled epidural analgesia with ropivacaine/fentanyl in off-pump coronary artery bypass grafting

ninety-three patients were scheduled for off-pump coronary artery bypass (opcab) under propofol/fentanyl anesthesia. day before surgery patients were asked for informed consent and randomized into three postoperative analgesia regimens aiming at a visual analog scale (vas) score \<30 mm at rest. the control group (n=31) received intravenous fentanyl 10 µg/ml postoperatively 3-8 ml/h. after placement of an epidural catheter at the level of th2-th4 before opcab, a thoracic epidural infusion (ei) group (n=31) received epidural anesthesia (ea) intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous ei of ropivacaine 0.2% 3-8 ml/h and fentanyl 2 µg/ml postoperatively. the patient-controlled epidural analgesia (pcea) group (n=31), in addition to ea and ei, received pcea (ropivacaine/fentanyl bolus 1 ml, lock-out interval 12 min) postoperatively. hemodynamics and blood gases were measured throughout 24 h after opcab.

Eligibility criteria:
inclusion criteria: * presence of coronary artery disease * asa ii-iii * elective off-pump coronary artery bypass exclusion criteria: * age \< 18 years * severe valve dysfunction or peripheral vascular disease * simultaneous interventions (carotid endarterectomy, aneurysm repair, etc.) * transfer to cpb during surgery

Keywords: epidural analgesia opcab pcea